Anivive, a software-driven pet health company, today announced the successful completion of its pivotal field study evaluating the safety and effectiveness of LAVERDIA®-CA1 (verdinexor tablets) in ...

Palo Alto Networks® , the global cybersecurity leader, today announced the appointment of Helle Thorning-Schmidt, former prime minister of Denmark, and Ralph Hamers, former chief executive officer of ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

Humanity Protocol is partnering with genomics company Prenetics, to collaborate on blockchain-based identity verification and ...

CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...

The lawsuit against the company was filed in August 2022. Seattle-based Parse Biosciences secured another major legal victory in its patent dispute with 10x Genomics Inc. (Nasdaq: TXG).

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel ...

SAN DIEGO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO)(the “Company”) today announced that it will effect a reverse stock split of its issued and outstanding common ...

China has put Illumina on its ‘unreliable entity list’ after the US imposed sanctions on Beijing Genomics Institute, also a ...